Online inquiry

IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1491MR)

This product GTTS-WQ1491MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD79B gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000626.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 974
UniProt ID P40259
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ1491MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2559MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 479
GTTS-WQ12817MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMS721
GTTS-WQ15621MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ11281MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ14432MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ14561MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aCD1919
GTTS-WQ15719MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VIR-7831
GTTS-WQ529MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 4D11
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW